Main / Racing / Sparcl trial ppt slides
Sparcl trial ppt slides
Name: Sparcl trial ppt slides
File size: 145mb
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was designed to determine whether a daily dose of 80 mg of atorvastatin. in Cholesterol Levels trial Patients with prior stroke/TIA are at risk for future cardiovascular (CV) events; Statins stroke incidence in SPARCL: Study design. 18 Oct SPARCL OVMC LANDMARK TRIALS SERIES Amarenco P, et al. CLINICAL QUESTION For patients prior stroke or TIA, does HIGH-DOSE.
The SPARCL study and other evidence led the American Heart (AHA/ASA) to recommend in-hospital initiation of statin therapy for patients with stroke or. SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels Patients with a history of stroke or TIA months prior to study entry (); LDL . SPARCL was a prospective, double-blind, and were followed for an average of years.7 Stroke, or a TIA, was diagnosed.
In addition to individual disclosures, the faculty of tonight's presentation have . But there were questions asked about the SPARCL trial, because 25% of the. SPARCL Trial Overview 1 doubled blinded, placebo-controlled trial evaluating the efficacy of high dose atorvastatin for . NEJM ;(6); Presentation on theme: "SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial."— Presentation transcript: 1 SPARCL Stroke. SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels A free PowerPoint PPT presentation (displayed as a Flash slide show) on. PPT - SPARCL PowerPoint Presentation - ID
3 Dec There was no significant mortality difference, although the trial was not adequately SPARCL was criticized for receiving industry funding. 10 Mar n engl j med ;6 august 10, The new . sive Reduction in Cholesterol Levels (SPARCL) trial was designed to. 13 Feb Nevertheless, the SPARCL trial has been influential, and has informed the AHA/ ASA recommendation for statin therapy in In-Depth [randomized, controlled study]: Published in NEJM in , the SPARCL trial sought to. 26 Dec The statin dose used in the SPARCL trial, which was sponsored by Pfizer by significant decreases in relative risk for cardiovascular events.